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ABSTRACT
Introduction Visceral leishmaniasis (VL) is a neglected 
parasitic disease with a high fatality rate if left untreated. 
Endemic in Morocco, as well as in other countries in the 
Mediterranean basin, VL mainly affects children living 
in rural areas. In Morocco, the direct observation of 
Leishmania parasites in bone marrow (BM) aspirates is 
used to diagnose VL and meglumine antimoniate (SB) is 
the first line of treatment. Less invasive, more efficacious 
and safer alternatives exist. In this study we estimate the 
cost-effectiveness of alternative diagnostic-therapeutic 
algorithms for paediatric VL in Morocco.
Methods A decision tree was used to estimate the 
cost-effectiveness of using BM or rapid diagnostic tests 
(RDTs) as diagnostic tools and/or SB or two liposomal 
amphotericin B (L-AmB) regimens: 6-day and 2-day 
courses to treat VL. Incremental cost-effectiveness ratios, 
expressed as cost per death averted, were estimated 
by comparing costs and effectiveness of the alternative 
algorithms. A threshold analysis evaluated at which price 
L-AmB became cost-effective compared with current 
practices.
Results Implementing RDT and/or L-AmB treatments 
would be cost-effective in Morocco according to the WHO 
thresholds. Introducing the 6-day course L-AmB, current 
second-line treatment, would be highly cost-effective if 
L-AmB price was below US$100/phial. The 2-day L-AmB 
treatment, current standard treatment of paediatric VL in 
France, is highly cost-effective, with L-AmB at its market 
price (US$165/phial).
Conclusions The results of this study should encourage 
the implementation of RDT and/or short-course L-AmB 
treatments for paediatric VL management in Morocco and 
other North African countries.
INTRODUCTION
Visceral leishmaniasis (VL), also known as 
kala-azar, is a neglected protozoal disease 
transmitted by sandflies.1 VL, caused by 
Leishmania infantum, is endemic in the Medi-
terranean basin, southern Caucasus, China 
and South America.1 Fatal unless treated, in 
northern African countries VL mainly affects 
children living in rural areas with low access 
to diagnosis and treatment.2 3 In Morocco, 
where an average of 152 cases were reported 
from 2004 to 2008 and 300 to 600 cases are 
estimated per year,4 VL is diagnosed and 
treated at district hospitals. According to the 
national guidelines,5 VL can be diagnosed by 
microscopic examination of bone marrow 
(BM) aspirate or using serological tests (eg, 
ELISA and Immunofluorescence Antibody 
Assay) in patients presenting with clinical 
symptoms: splenomegaly, fever and pancy-
topenia. Serological tests are usually not 
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Key questions
What is already known about this topic?
 ► Visceral leishmaniasis (VL) is a life-threatening 
parasitic disease endemic in the Mediterranean 
basin.  In Morocco and other countries in northern 
Africa VL mainly affects children living in poor rural 
areas. 
 ► In Morocco, VL is diagnosed by microscopy which 
requires an invasive procedure (bone marrow 
(BM) aspiration) and cases are treated using a toxic 
drug (meglumine antimoniate) which requires long 
and painful intramuscular injections. 
 ► Less invasive diagnostic tools (rapid diagnostic 
tests  (RDTs)) and safer, short-course and more 
effective antileishmanial drugs (liposomal 
amphotericin B (L-AmB)) are available but their 
use in low-income and middle-income countries is 
limited due to their high cost. 
What are the new findings?
 ► Our cost-effectiveness analysis shows that using 
RDTs would be more effective and less costly than 
BM aspiration to diagnose paediatric VL. 
 ► More importantly, our study shows that treating 
children suffering from VL with short-course 
L-AmB regimens is also cost-effective in Morocco. 
Recommendations for policy
 ► RDT and short-course L-AmB regimens should be 
implemented to diagnose and treat paediatric VL in 
Morocco and other countries in the Maghreb. 
 ► The Ministries of Health in those countries and WHO 
should negotiate with the manufacturer of L-AmB to 
reduce the price of this drug to ensure all patients 
with VL in North Africa have access to the best 
treatment. 
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available in public hospitals so BM aspiration is the stan-
dard diagnostic method.6 BM, which is usually obtained 
by sternal aspiration in children, is an invasive and 
painful procedure with a variable and low sensitivity, 
ranging from 60% (95% CI 50% to 90%) to 77% (95% 
CI 71.5% to 81.5%).7 8 Meglumine antimoniate (SB) 
(20 mg of SB/kg/day parenterally for 20 days) is the first 
line of treatment. SB treatment is painful, requires long 
hospitalisation and is highly toxic. The case fatality rate 
in children treated with SB is high in North African coun-
tries9–16compared with other endemic countries such as 
Greece.17 Other factors such as concomitant infections or 
late diagnosis, more common in North African patients 
with VL, may increase the toxicity-related mortality. Lipo-
somal amphotericin B (L-AmB) (18–25 mg/kg in six 
doses—days 1 to 5 and 10) is the second line of treat-
ment in Morocco.5 L-AmB is the safest and most effective 
antileishmanial drug but it is rarely used in Morocco6 
due to its high cost.18 Thus, the current standard of 
care of paediatric VL in Morocco is the examination of 
BM aspirates and the administration of 20 doses of SB 
for diagnosis and treatment, respectively. The median 
total cost associated to managing a paediatric VL case in 
Morocco is US$520 (IQR US$316–658).6 More sensitive 
and less invasive tests and safer drugs for VL exist but are 
not implemented in Morocco mainly due to high costs.
In the past 15 years, there have been major advances in 
the management of paediatric VL caused by L. infantum. 
An accurate rapid diagnostic test (RDT) for VL is avail-
able,19 with an associated sensitivity of 83.2% (95% CI 
74.1% to 90.8%) and specificity of 99.8% (95% CI 99% to 
100%) (Cruz et al, unpublished). This RDT only requires 
a small blood sample obtained by finger prick and could 
be used as a diagnostic tool in hospitals attending VL 
suspects.1 More importantly, SB has been replaced by 
L-AmB to treat VL in European countries where this 
disease is also endemic. Two L-AMB regimens are being 
implemented: 3–4 mg/kg/day of L-AmB on days 1 to 5 
and 10 (total dose 18–24 mg/kg)20–22 in Spain and Italy 
and 10 mg/kg daily of L-AmB for two consecutive days 
(total dose 20 mg/kg)17 23 24 in France and Greece. Please 
note that the treatment used in Spain and Italy is the 
second-line treatment in Morocco.5 These treatments 
which are expensive due to the cost of L-AmB (US$165 
per phial)23 have been proven cost-effective in Europe as 
they are safer, more efficacious and reduce the hospital-
isation of patients compared with SB treatments.17 21 23
The reasons explaining why a child suffering from 
VL in Morocco does not receive the same treatment as 
a child suffering the same disease 14 km further north 
(the distance between Morocco and Spain) are usually 
associated to the cost of L-AmB. However, the cost-effec-
tiveness of the shorter and safer L-AmB treatments for 
VL has never been assessed in the Moroccan or North 
African context. Furthermore, the cost of L-AmB can be 
reduced. WHO and Gilead, the manufacturer of Ambi-
some, the only L-AmB currently registered as a VL drug, 
agreed to reduce the price of L-AmB to US$18 per phial 
for the public sector and not-for-profit organisations to 
treat patients with VL in the most VL-endemic countries 
(eg, India, Nepal or Bangladesh). In 2015 WHO received 
a request from the ministries of health of Algeria, 
Morocco and Tunisia so as to get L-AmB at a WHO-nego-
tiated price with the aim of introducing it as the first-line 
treatment for VL. WHO discussed the situation with the 
manufacturer, Gilead, which agreed to move forward 
and initiate the formalities to make that happen (Ruiz-
Postigo, personal communication).
In this study we estimated the cost-effectiveness of 
using RDT to diagnose and/or L-AmB regimens to treat 
paediatric VL in Morocco compared with current stan-
dard of care (ie, BM and SB). We also estimated the 
impact of reducing the cost of L-AmB on the cost-ef-
fectiveness ratios. The results of this study should help 
the ministry of health and paediatricians in Morocco in 
deciding if the RDT and/or L-AmB treatments should 
be implemented to manage paediatric patients with VL. 
The results will also inform the ministry of health on the 
current negotiations to reduce the cost of L-AmB. The 
information generated in this study may trigger changes 
in the health policies in Morocco, and in other North 
African countries facing similar clinical and epidemiolog-
ical challenges.
METHODS
Study design
Current practices for the management of suspected cases 
of VL in Morocco; microscopic examination of BM for 
diagnosis and treatment with 20 mg/kg a day of SB for 
20 days (strategy A), were compared with the adoption 
of RDT for diagnosis and two different short-course regi-
mens of L-AmB: (1) 6-day course: 3 mg/kg a day on days 
1 to 5 and 10,21 and (2) 2-day course: 10 mg/kg a day for 
two consecutive days.17 24
Six strategies were compared. By combining the two 
diagnostic tools (BM and RDT) and the three VL treat-
ments (SB, and two L-AmB regimens) the following 
strategies (A to F) were considered: (A) BM for diagnosis 
and SB for 20 days for treatment (current practices); 
(B) BM for diagnosis and 6-day course L-AmB for treat-
ment, (C) BM for diagnosis and 2-day course L-AmB for 
treatment, (D) RDT for diagnosis and SB for 20 days 
as treatment, (E) RDT for diagnosis and 6-day course 
L-AmB for treatment, and (F) RDT for diagnosis and 
2-day course L-AmB for treatment (table 1).
A decision tree was employed to evaluate the cost-ef-
fectiveness of the different strategies by estimating 
the costs and effects associated with each strategy of a 
theoretical cohort of 100 children with suspected VL 
(figure 1).25 A suspect case was defined as a child living 
in a VL-endemic area in Morocco presenting with VL 
symptoms: persistent fever and splenomegaly. In our 
model a VL suspect attending a district hospital in 
Morocco was either diagnosed by BM aspiration or RDT. 
If the patient was confirmed as a patient with VL it was 
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Table 1 Diagnostic-treatment strategies for paediatric visceral leishmaniasis (VL) management in Morocco
Strategy Diagnosis Treatment
  A* Bone marrow aspiration and 
microscopic examination
20 mg/kg/day of SB† for 20 days†
  B 3 mg/kg/day of L-AmB‡ on days 1 to 5 and 10 (6-day course)21
  C 10 mg/kg daily of L-AmB for two consecutive days (2-day course)17 24
  D Rapid diagnostic test 20 mg/kg/day of SB for 20 days
  E 3 mg/kg/day of L-AmB on days 1 to 5 and 10 (6-day course)
  F 10 mg/kg daily of L-AmB for two consecutive days (2-day course)
*Current practice in Morocco.
†SB, meglumine antimoniate. 
‡L-AmB, liposomal amphotericin B.
then treated either with SB, a 6-day course or a 2-day 
course L-AmB.
Modelled effects
The probabilities used in the decision analysis model 
were obtained from previous studies. The probability that 
a VL suspect was a true VL case was obtained from the 
prevalence of the disease among the suspected cases in 
Morocco.6 Sensitivity and specificity of the diagnostic tools 
(BM or RDT) were adopted from studies on L. infantum 
VL,8 including an unpublished work by Cruz et al.
Once diagnosed, sensitivity and specificity of the diag-
nostic test determined four possible outcomes. First, 
a true positive case would imply treating the patient, 
resulting in three different outcomes depending on the 
probabilities associated to the treatment: complete cure, 
death or relapse. When a relapse occurs, we assumed 
the patient would receive the same treatment as earlier 
and be cured or die according to the respective proba-
bilities. Second, a true negative case would correctly rule 
the patient out and exit the model alive. Third, a false 
positive case would wrongly be treated with a small risk 
of death related to the toxicity of the drug used.26 Finally, 
although a false negative case would translate into no 
treatment, we assumed that the severity of symptoms 
would make the practitioner take a BM test to confirm VL 
infection. The patient would be cured or die according 
to the probabilities associated to the treatment.
All probabilities of cure, death and relapse associated 
with SB,3 9–17 27 28 as well as both L-AmB regimens,17 20–24 29 30 
were obtained from a literature search on VL caused by 
L. infantum in North Africa or Europe (see online supple-
mentary annex S1). Due to the lack of reliable estimates in 
Morocco, we disregarded patients’ perception of health 
improvements or drug resistance issues; and assumed full 
compliance to treatment given that the nature of treat-
ment regimens implied hospitalisation for completion. 
However, we included relapses, as they are commonly 
reported in the Mediterranean basin.17
Hospitalisation, treatment and diagnostic costs
Hospitalisation costs, including diagnostic tests and 
treatments, were retrieved from primary data collected 
in 2014.6 Individual clinical and cost records consisted 
of resources for the management of confirmed VL cases. 
The use of each resource was multiplied by the respective 
unit official price to obtain an estimation of costs for the 
healthcare provider.31 32
In our model, patients received the complete treatment 
during hospital admission. We used the mean hospital-
isation daily cost for inpatient VL and multiplied it by 
the length of stay (number of days) to estimate the total 
hospitalisation cost, which included hotel costs and other 
diagnostic tests and treatments not directly related to VL 
treatment and diagnosis. The total number of hospital-
isation days depended on the test capacity to diagnose 
VL and the treatment duration related to each drug 
regimen. The number of days before starting treatment 
slightly varied depending on the diagnostic tool consid-
ered, while the number of days after starting treatment 
substantially differed between drug regimens (table 2).
The VL diagnosis cost reported in a previous study in 
Morocco was used.6 A personal communication estima-
tion from the WHO’s Head of the Leishmaniasis Control 
Programme (Ruiz-Postigo, personal communication) was 
used as price of an RDT which was later contrasted by 
other works published in the literature.33 34
Since the VL treatment cost directly depended on the 
number of phials required according to patient’s weight, 
we applied the distribution of the patients’ weights in 
our sample to the theoretical cohort of 100 children in 
our model (see online supplementary material in Tach-
fouti et al).6 We employed the price of L-AmB reported 
in the literature,23 and used the local price of SB6 incor-
porating uncertainty by considering the international 
market price.35 As a supplementary analysis we used 
the WHO-Gilead negotiated price (US$18 per phial) of 
L-AmB. The total cost of VL treatment was estimated for 
the three drug regimens as:
 ×
×
×
 
being
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Figure 1 The decision tree. The figure illustrates the possible outcomes of a theoretical visceral leishmaniasis (VL) suspect 
attending the Moroccan healthcare. The outcome is determined by the diagnostic tool (bone marrow (BM) aspiration or 
rapid diagnostic test (RDT)) and treatment regimen (meglumine antimoniate (SB), 2-day course or 6-day course liposomal 
amphotericin B (L-AmB)) used, which represent the six strategies analysed in the study.
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Table 2 Input variables of the deterministic and probabilistic cost-effectiveness analysis
Input variable Likeliest (Low–high) Probability distribution Source
Costs of management of VL (US$)
Cost of VL diagnosis
  BM cost (95% CI) 21.40 (17.41 to 25.79) γ 6 32
  Serology cost (95% CI) 11.77 (9.58 to 14.19) γ 6
  RDT cost (min–max) 1.10 (1.00 to 2.20) Triangular asymmetrical Ruiz-Postigo (personal 
communication),33 34
Cost of VL treatment (min–max)
  SB price 1.70 (1.20 to 3.40) Triangular asymmetrical 5 6 35
  L-AmB 50 mg/phial price 165.12 (150.00 to 230.00) Triangular asymmetrical 23
Rest of cost per hospitalisation day (IQR)
  Hospitalisation day 29.45 (19.00 to 37.00) γ 6
Days at the hospital (days—IQR)
  Before diagnosis BM 2.00 (1.00 to 6.00) Log-normal 6
  Before diagnosis RDT 1.00 (0.00 to 2.00) Log-normal 6
  After diagnosis SB 20.00 (12.00 to 31.00) γ 6
  After diagnosis 6-day course L-AmB 10.00 (7.28 to 13.15) γ 6
  After diagnosis 2-day course L-AmB 2.00 (1.46 to 2.63) γ 6
Treatment courses (days)
  SB 20.00 Point estimate 5
  Six-day course L-AmB 6.00 Point estimate 21
  Two-day course L-AmB 2.00 Point estimate 17 24
Epidemiology (95% CI)
  VL prevalence over VL suspects 0.7346 (0.6126 to 0.9177) β 6
Treatment outcome probabilities
Meglumine antimoniate (Glucantime) 20 mg/kg/
day (95% CI)
  CFR SB 0.0581 (0.0416 to 0.0772) β 9–17
  Relapse SB 0.0460 (0.0137 to 0.0964) β 14 16 17 27
  Cure rate SB 0.8959 (0.8745 to 0.9156) β 3 9 11 13–17 28
Six-day course L-AmB (Ambisome) 3 mg/kg/day 
(95% CI)
  CFR 6-day course L-AmB 0.0076 (0.0069 to 0.0084) β 17 20–23 30
  Relapse 6-day course L-AmB 0.0418 (0.0322 to 0.0526) β 17 20–23 30
  Cure rate 6-day course L-AmB 0.9506 (0.9375 to 0.9622) β 17 20–24 29 30
Two-day course L-AmB (Ambisome) 10 mg/kg/
day (95% CI)
  CFR 2-day course L-AmB 0.0001 (0.0000 to 0.0004) β 17 23
  Relapse 2-day course L-AmB 0.0227 (0.0185 to 0.0274) β 17 23
  Cure rate 2-day course L-AmB 0.9772 (0.9545 to 0.9922) β 17 23 24 29
Diagnostic outcome probabilities (95% CI)
  BM sensitivity 0.7700 (0.7150 to 0.8150) β 8
  BM specificity 0.9900 (0.9400 to 0.9970) β 8
  RDT sensitivity 0.8320 (0.7410 to 0.9010) β Cruz (unpublished)
  RDT specificity 0.9980 (0.9900 to 1.0000) β Cruz (unpublished)
Macroeconomic (min–max)
  Discount rate 3.00% (0.00% to 5.00%) Point estimate 6
BM, bone marrow and microscopy; CFR, case fatality rate; L-AmB, liposomal amphotericin B; RDT, rapid diagnostic test; SB, meglumine 
antimoniate; VL, visceral leishmaniasis. 
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Table 3 Probabilistic results: cost-effectiveness (C-E) analysis of management of 100 VL suspects (L-AmB at market price)
Strategy (diagnosis 
+treatment)
Cost per 100 suspect VL cases 
(US$)
Effectiveness (E) per 100 
suspect VL cases
C/E ratio
Incremental C/E 
(ICER)Cost (C)±SE
Incremental 
cost Deaths±SE
Deaths 
averted
D (RDT + SB) 66 467.35±1088.61 5.01±0.03 669.70
A (BM + SB)* 76 736.47±1197.66 10 269.12 5.22±0.03 −0.21 809.61 Dominated
F (RDT + 2-day L-AmB) 82 478.82±394.81 5742.34 0.29±0.00 4.93 827.17 1165.00
C (BM + 2-day L-AmB) 92 854.82±556.84 10 376.00 0.39±0.00 −0.10 932.21 Dominated
E (RDT + 6-day L-AmB) 120 740.81±592.47 27 885.99 1.10±0.01 −0.70 1220.80 Dominated
B (BM + 6-day L-AmB) 131 035.37±719.90 10 294.56 1.29±0.01 −0.19 1327.48 Dominated
*Current practices in Morocco.
Note: Strategies sorted by cost. Each strategy is compared with the one immediately above.
BM, bone marrow; ICER, incremental cost-effectiveness ratio; L-AmB,liposomal amphotericin B; RDT,rapid diagnostic test; SB: meglumine 
antimoniate; VL, visceral leishmaniasis.
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Costs were discounted at a 3% rate, converted to 
US$2014 and inflation adjusted.36 37
Analyses
Cost-effective analysis
We undertook a deterministic cost-effective analysis by 
taking the most likely values for the parameters used in 
the model. We further adopted a probabilistic approach 
to incorporate uncertainty in the model parameters.38 
As showed in table 2, parameters were expressed as 
probability distributions. Distributions and ranges were 
obtained either from our estimations6 or from published 
articles.3 5 6 9 11–17 20–24 27–30 32–35 39–42 For those parameters 
where no data were available, probability distributions 
were constructed assuming standard deviations (SD) of 
1%, 10%, 15%, 20% or 100%, depending on the param-
eter’s level of potential uncertainty.
For each strategy, we computed associated expected 
costs and deaths in the absence of disease detection or 
adequate response to treatment. Incremental costs and 
deaths averted were used to compute the incremental 
cost-effectiveness ratios (ICERs) between two strategies. 
Monte Carlo simulations were used to estimate 95% CIs 
for all input parameters and for model outcomes.43
WHO cost-effectiveness thresholds for disability-ad-
justed life-years averted were employed to identify 
cost-effective (ICER below three times the World Bank esti-
mation of 2014 Moroccan Gross domestic product (GDP) 
per capita) and highly cost-effective alternatives (ICER 
below the World Bank estimation of 2014 Moroccan GDP 
per capita, US$3 190).44 If an alternative strategy would 
reduce the mean cost with respect to current practices it 
will be denoted as cost-saving.
Acceptability curves
Acceptability curves were constructed to represent the 
probability of the alternative strategies to be cost-effective 
depending on a theoretical willingness-to-pay per death 
averted.45
Sensitivity analysis
We undertook one-way sensitivity analysis to determine the 
impact on cost-effectiveness results of changes in selected 
parameters (see online supplementay table S2). These 
checks included varying the cost of BM at a reduced price 
($5.90 per unit), the price of SB at the officially subsi-
dised price ($1.70 per phial), the prevalence level among 
the clinical suspects (decreasing it to 50% of suspects and 
increasing it to 100%), a fixed reduced mortality rate 
(2%) and increased efficacy (93.4%) for SB regimen, 
assumed 100% cure in patients treated again with L-AmB, 
and adopting alternative values of BM sensitivity (60%, 
ranging from 50% to 90%) and specificity (100%),7 as 
well as RDT sensitivity (92%, 91.49%–92.92%) and speci-
ficity (95%, 94.30%–95.48%).19
Moreover, we checked for changes in results derived 
from a reduction in the uncertainty of parameters 
collected on site (days before receiving diagnosis and 
days until receiving treatment), as parameters that were 
modelled based on individual data accounted higher 
uncertainty than those in which an SD was assumed. 
We applied specific SDs of 15% to the most likely values 
following log-normal distributions, as done for L-AmB 
parameters.
Threshold analysis
We finally carried out a probabilistic threshold anal-
ysis to identify at which price the adoption of L-AmB 
regimens (strategies B and C) became cost-effective 
interventions compared with current practices. We 
graphically represented ICERs and their respective CIs 
for marginal reductions of L-AmB price from its market 
price to zero.
Microsoft Excel 2007 was used for data analysis.
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RESULTS
Cost-effective analysis
Table 3 presents the expected costs and effects of each 
strategy of the probabilistic analysis taking the market 
price of L-AmB, ordered from the cheapest to the most 
expensive. Each strategy was compared with the one 
immediately cheaper. Strategy D was the least costly 
strategy and dominated current practices (strategy A) 
by slightly increasing the deaths averted due to improve-
ments of the diagnostic performance. Current practices 
(strategy A) in Morocco remained the least effective 
strategy, while strategy F resulted in the most effective 
one. Strategy B although highly effective, was the most 
costly strategy of all the combinations of diagnosis and 
treatment considered in the study. Overall, strategies with 
treatment regimens based on L-AmB (strategies B, C, E 
and F) were more expensive but averted more deaths 
than strategies based on SB (strategies A and D), regard-
less of the diagnostic tool used. Two-day course L-AmB 
strategies (strategies C and F) averted more deaths and 
were clearly cheaper than 6-day course L-AmB strate-
gies (strategies B and E). Furthermore, strategies using 
RDT as a diagnostic tool (strategies D, E and F) were 
less costly and slightly more effective than strategies 
using BM aspiration. Results of the deterministic analysis 
(see online supplementary table S3) were similar to those 
obtained from the probabilistic analysis.
Table 4 shows the results of the cost-effectiveness anal-
ysis when comparing current practices (strategy A) to 
each remaining strategy. Adopting RDT as the diagnostic 
tool if SB is maintained as the treatment regimen (strategy 
D) it dominated current practices by reducing the cost 
by US$10 269 (95% CI 9 412 to 11 127) without decreasing 
efficacy. When comparing the use of L-AmB maintaining 
BM as the diagnostic tool, only the 2-day course regimen 
(strategy C) became cost-effective compared with current 
practices, as the 6-day course L-AmB (strategy B) ICER 
was lower than the WHO threshold. When compared with 
current practices, strategy C allowed to avert 4.82 (95% 
CI 4.77 to 4.88) deaths by increasing to US$16 118 the 
cost of managing a 100 paediatric VL suspects, resulting 
in an ICER of US$3 486 (95% CI 3 059 to 3 913) per 
death averted. By adopting both the RDT and the 
L-AmB treatment regimens, the 2-day course (strategy F) 
became a highly cost-effective strategy (value below the 
GDP per capita) as it averted almost 4.93 (95% CI 4.87 to 
4.98) deaths by increased cost of managing a 100 paedi-
atric VL suspects in US$5 742 US$ (95% CI 3 468 to 8 
017), resulting in an ICER of US$1 136 (95% CI 658 to 
1 614) per death averted. Strategies in which treatment 
consisted of a 6-day course L-AmB (strategy B and E) 
were not cost-effective alternatives to current practices 
at the market price of L-AmB. As shown in the supple-
mentary analysis, if Morocco would get L-AmB at US$18/
phial, all the strategies using L-AmB-based regimens 
would be cost-saving compared with strategies using SB 
(see online supplementary table S4).
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Figure 2 Cost-effectiveness acceptability curves. (A) Compares current practices (strategy A: bone marrow (BM) aspiration 
to diagnose and meglumine antimoniate (SB) to treat) with the adoption of two different short-course liposomal amphotericin 
B (L-AmB) regimens: strategy B - light grey and strategy C - dark grey. (B) Compares current practices with the adoption of 
both, rapid diagnostic test (RDT) to diagnose and two different short-course L-AmB regimens: strategy E - light grey and 
strategy F - dark grey. For both figures, the y-axis represents the probability of the strategies to be cost-effective for each 
level of willingness-to-pay per death averted (x-axis). The vertical lines represent thresholds for cost-effective(US$9 571, 
corresponding to three times the Moroccan GDP per capita) and high cost-effective (US$3 190, corresponding to the 
Moroccan GDP per capita) interventions. 
Acceptability curves
Figure 2 shows the cost-effectiveness acceptability curves 
when the market price of L-AmB is used. When evalu-
ating the introduction of L-AmB (figure 2A), strategy C 
was cost-effective in 74% of simulations and strategy B in 
24% of them. When evaluating the adoption of RDT and 
L-AmB (figure 2B), strategy F was cost effective in 82% 
of simulations, and strategy E in 36% of them. Two-day 
L-AmB regimen strategies involved cost-savings in 25% 
(strategy C) and 32% of simulations (strategy F).
Sensitivity analysis
Modifying the SB or BM prices, the sensitivity and spec-
ificity of BM or RDT, SB mortality and efficacy and VL 
prevalence among suspects did not alter the outcome of 
the cost-effectiveness analysis (see online supplementary 
table S5). More precisely, the univariate analysis of the 
BM price, alternative sensitivity and specificity values for 
BM and RDT and VL prevalence had a negligible impact 
on costs and effectiveness, while fixing SB mortality rate 
to 2% increased effectiveness but costs associated with 
those alternative remained invariant, as were the conclu-
sions of the cost-effectiveness evaluation. Decreasing the 
SB price to its subsidised value reduced the total cost of 
SB-based strategies (A and D) by 12% to 14%.
Threshold analysis
Results from the threshold analysis are represented in 
figure 3 and detailed in online supplementary table S6. 
Strategy B (6-day L-AmB) was not cost-effective when 
the cost per L-AmB phial was above US$140. The 6-day 
L-AmB treatment would be cost-effective with phial prices 
ranging from US$100 to US$140 and would be highly 
cost-effective with L-AmB price below US$100/phial 
(ICER of 3865; 95% CI 3182 to 4548). If the price per 
phial of L-AmB could be reduced below US$75, the 6-day 
L-AmB treated would be cost saving. Strategy C (2-day 
L-AmB) remained cost-effective for all prices of L-AmB 
considered (max US$180/phial) and resulted highly 
cost-effective at prices of US$175/phial (ICER of 3 073; 
95% CI 2527 to 3 619) or below. If the price of L-AmB was 
reduced below US$140/phial the 2-day L-AmB regimens 
(strategy C) would be cost saving.
DISCUSSION
Based on the results of this study the Ministry of Health 
(MoH) in Morocco should implement the use of RDT 
to diagnose paediatric patients with VL without further 
delay. The treatment of patients with VL should also be 
reviewed: L-AmB should be used to treat VL in children in 
Morocco. The MoH in Morocco and other North African 
countries in collaboration with WHO should negotiate 
the price of L-AmB with Gilead.46 The negotiations 
should aim at reducing the cost of an L-AmB phial below 
US$140 so the 6-day 3 mg/kg L-AmB regimen, currently 
the second line of treatment in Morocco,5 replaces the 
toxic SB-based treatment. However a price below US$75 
per phial would be preferred as it would ensure this 
L-AmB-based regimen is implemented immediately as 
it will be cost-saving. This cost per phial remains signifi-
cantly higher than the one currently applied in other 
VL-endemic countries like India or Bangladesh (US$18/
phial). If Morocco and other countries in North Africa 
could purchase L-AmB phials at this cost, treating VL in 
children would be significantly cheaper and safer than 
using SB (see online supplementary table S4).
As an alternative, the MoH in Morocco could adopt the 
treatment regimen used in France and Greece to treat 
paediatric patients with VL: 2-day 10 mg/kg L-AmB.17 22 
This strategy is cost-effective even when the market price 
of L-AmB is used (US$165/phial). However, as before, 
reducing the cost per phial (below US$140) would facil-
itate the implementation of this L-AmB-based regimen. 
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Figure 3 Threshold analysis. The figure evaluates at which price the use of liposomal amphotericin B (L-AmB) became cost-
effective compared with current practices. The horizontal lines represent the cost-effective (CE) (US$9 571) and highly CE 
(US$3 190) thresholds. Strategy B is a combination of diagnoses based on bone marrow (BM) and microscopic examinations 
and treatment of 6-day course L-AmB, while strategy C is a combination of diagnosis based on BM and microscopic 
examinations and treatment of 2-day course L-AmB.
There is evidence that the 2-day L-AmB regimen is a safe 
and effective treatment for paediatric VL17 22 but it is still 
not recommended by WHO.1 Clinical trials in Morocco 
and other countries in North Africa should be conducted 
to demonstrate the efficacy of 2-day L-AmB regimen to 
treat L. infantum VL in children in the region. These 
results may prove valuable for other regions with similar 
VL epidemiology, such as the Caucasus,47 Albania,48 
South America or China.1 However, further research is 
needed to evaluate if the introduction of L-AmB-based 
regimens would yield cost-effective results in regions with 
different health systems and economic contexts.
The adoption of RDT and L-AmB-based regimens to 
manage patients with VL in the Maghreb is supported by 
experts in the region46 as they have a number of advan-
tages, in particular from the patient’s perspective, that 
have not been considered in our study. For example 
using RDT would reduce the discomfort in children as 
they are significantly faster, less invasive and less painful 
than BM aspiration.29 L-AmB regimens are safer, have 
fewer side effects and lower case fatality rates than SB,49 
and they are less painful than SB treatments that require 
intramuscular injections for 20 days. L-AmB treatments 
also reduce the number of hospitalisation days. This has 
an impact on the cost of the treatment as shown in our 
and other studies,23 and it also benefits the patients and 
their families by reducing the indirect costs associated 
with caregivers accompanying the patients, such as the 
time lost from productive work or housekeeping activi-
ties, cost of transport and other out-of-pocket expenses. 
Those indirect costs can be significant in the VL 
context.31 50 The results of our cost-effectiveness analysis 
are thus conservative. Including the patient’s perspective 
would have increased the cost-effectiveness of the alter-
native strategies proposed.
In our study we evaluated the use of RDT to diag-
nose VL at the hospital level as it is one of the options 
suggested by WHO.1 We did not assess the use of RDT 
in primary health centres as the prevalence of VL in 
Morocco is lower compared with in countries where this 
strategy is implemented (eg, India).51 However the use 
of RDT in peripheral health centres to triage or diag-
nose VL suspects may be an option to consider if the 
VL-endemic areas in Morocco continue to expand.52 
Similarly, in our model we assumed that SB treatment was 
performed in the hospital as indicated by the national 
guidelines.5 However a recent study6 showed that a signif-
icant number of children suffering from VL in Morocco 
receive an ambulatory treatment in primary health 
centres. This approach reduces considerably the costs per 
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patient (US$307) but it is not recommended by experts 
or WHO1 as SB treatment requires close monitoring.
The cost data used in the model were based on indi-
vidual-level data collected in hospitals in Morocco.6 In 
contrast, the estimates of RDT, BM accuracy and L-AmB 
treatments efficacy used in the model were obtained 
from other L. infantum-endemic areas, as clinical trials 
evaluating their performance are scarce in North African 
countries.53 Notwithstanding, as shown in the sensitivity 
analysis, varying those key parameters did not have 
a significant impact on the cost-effectiveness results. 
Our model neither considers the natural history of 
the disease,54 nor a dynamic transmission of it,55 but it 
remains easy to understand and potentially more useful 
for health policy decisions.
Despite the results of our cost-effectiveness study both 
BM and SB have their place in paediatric VL manage-
ment in Morocco. For example, BM is used to search for 
haematological malignancies such as leukaemia, which 
are part of the differential diagnosis for VL. And SB 
treatments, which are still in use in some European coun-
tries,29 48 56 can help treat patients with VL not responding 
to L-AmB treatment.57
CONCLUSION
The high cost should not limit the use of better diag-
nostic tools and safer treatments to manage paediatric 
patients with VL in Morocco. The results of this study 
should trigger the implementation of RDT and L-AmB to 
diagnose and treat VL in children in Morocco and other 
countries in the Maghreb. The data generated should 
also help the MoH in those countries and WHO to nego-
tiate the price of L-AmB with Gilead to ensure all patients 
with VL in the Maghreb, and in particular paediatric 
patients, are treated with the best antileishmanial drug.
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